CareDx Q3 2026: NavDx Boosts Growth While Portfolio Refocus Signals More Durable Revenue

Overview: A 39% Revenue Rise on the NavDx and Services Engine

CareDx reported total revenue of $139 million for the third quarter ended September 30, 2026, up 39% year over year. The growth was led by Testing Services, which generated $119 million—a 65% year-over-year surge—along with a meaningful contribution from the Patient and Digital Solutions segment at $20 million, up 31% YoY.

The company highlighted a testing volume of roughly 75,900, a 51% year-over-year increase, including contributions from the NavDx program after its July 1, 2026 acquisition. GAAP net income was $19 million for the quarter, a notable improvement from $2 million in the third quarter of 2025, and Adjusted EBITDA reached $30 million, up from $15 million a year earlier. Cash flow from operations was $13 million.

Notably, the quarter excludes the Lab Products business, which the company divested on June 30, 2026, suggesting the current results reflect a higher-growth, lower-diversified portfolio focus.

Strategic Moves: Portfolio Refocus and Acquisitions

The press release emphasizes two big moves that shaped the quarter’s trajectory. First, the NavDx acquisition broadened CareDx’s commercial and clinical footprint in transplant genetics and precision medicine, expanding into additional use-cases and payer scenarios. Second, the company completed the acquisition of Naveris, Inc. for $160 million in cash with up to $100 million in contingent consideration, broadening the company’s platform in related diagnostics and potential data-rich offerings.

On the portfolio restructuring, CareDx completed the divestiture of its Lab Products business, effective June 30, 2026. The impact is a leaner, more execution-focused organization with the potential for improved margins and more concentrated investment in high-growth areas such as Testing Services and digital/clinical solutions.

Management also highlighted continued commercialization momentum for AlloHeme and HistoMap Kidney, aiming for CLIA readiness before year-end with launches targeted in 2027. The company also cited expanded clinical evidence for NavDx across multiple contexts of use, and ongoing portfolio-wide commercial execution—e.g., Epic Aura adoption and patient portal enrollment—supporting a more integrated care pathway for transplant patients.

Outlook: Revenue Forecast Raised, EBITDA on Track, and What It Means for EPS

CareDx raised its 2026 revenue guidance to a range of $520 million to $530 million and guided Adjusted EBITDA to $90 million to $100 million. This update implies an earnings cadence that could translate into a positive earnings per share (EPS) trajectory, depending on share count and non-cash items, even though the company does not publish an explicit quarterly EPS figure in the release. Investors will be watching how the revenue mix—strong Testing Services growth with NavDx synergies—translates into margin expansion and cash flow resilience in the second half of 2026 and into 2027.

Analysts’ EPS consensus and the potential for an earnings surprise will hinge on the pace of NavDx integration, NavDx’s cross-sell to CareDx’ existing customer base, and how quickly AlloHeme and HistoMap Kidney contributions scale into earnings. The updated revenue forecast signals confidence in the company’s strategy, but execution risk remains as management navigates integration milestones and payer dynamics in a rapidly evolving market for transplant diagnostics and precision medicine.

Implications for CareDx and Sector Peers

The Q3 performance paints a cohesive narrative: growth is increasingly driven by high-growth services and digital solutions, not just instrument or single-product sales. The NavDx expansion signals a broader trend in transplant diagnostics toward multi-product ecosystems that can cross-sell services and data-driven insights across the patient care journey. For peers in the sector, this sets a bar for portfolio strategy—lean into acquisitions that complement existing platforms and clear divestitures that sharpen a company’s growth runway and margin profile.

Clinically, the company’s emphasis on AlloHeme, HistoMap Kidney, and NavDx data—and the ongoing KOAR registry work—suggests a matured confidence in molecular results guiding patient management. If this translates to faster adoption, larger addressable markets, and stronger payer coverage, the sector could see a shift toward more integrated, data-forward models in transplantation and related oncology spaces.

Financially, CareDx’s improved EBITDA and positive quarterly GAAP earnings illustrate how a well-timed portfolio reconfiguration can unlock profitability even as growth platforms scale. The risk, of course, lies in integration execution, potential rate pressures from payers, and the durability of testing volumes in a healthcare environment that remains sensitive to budget cycles and commoditization pressure in laboratory services.

Conclusion: A Quarter of Strategic Clarity in a Complex Market

CareDx’s Q3 2026 results underscore a company moving beyond a broad, mixed portfolio toward a sharper, growth-oriented model. The 39% revenue uplift, the NavDx and Naveris expansions, and the Lab Products divestiture all point to a company leaning into higher-margin, recurring revenue lines and a more coherent go-to-market strategy. The raised revenue forecast and EBITDA guidance imply management’s confidence in sustaining the trajectory, even as investors weigh the efficiency of integrations and the durability of demand in transplant diagnostics and precision medicine.

For the sector, the lesson is clear: scale and integration matter more than ever. If CareDx can translate the quarterly momentum into sustained top-line growth and margin expansion, EPS could follow, supported by a more favorable revenue mix and stronger cash generation. The road ahead will test the mechanics of cross-sell dynamics, payer coverage, and the pace at which CLIA-ready programs like AlloHeme and HistoMap kidney can move from development into durable, revenue-generating franchises.